Sirnaomics will evaluate the safety and efficacy of STP705 to treat patients with squamous cell skin cancer. Credit: Valerie R. Yanofsky, Stephen E.Mercer, and Robert G. Phelps.

Sirnaomics has commenced a Phase IIb study to evaluate the safety and efficacy of its lead drug candidate, STP705, to treat patients with squamous cell skin cancer.

The two-part dose escalation, randomised, double-blind, placebo-controlled study will evaluate intralesional injection of the small interfering RNA therapeutic STP705 in 100 adult patients with squamous cell carcinoma in situ (isSCC).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The 30ug and 60ug dosing regimens from the Phase IIa study of the drug will be further evaluated in the run-in period of the trial, besides a third new dose level.

Sirnaomics founder, president and CEO Patrick Lu said: “In the recently concluded Phase IIa clinical trial of STP705 in isSCC, a high rate of patients achieved histological clearance in a dose dependent manner, which is the gold standard for skin cancer.

“As we initiate the Phase IIb trial, we are hopeful to learn more about the potential of this non-surgical, non-invasive treatment for common non-melanoma skin cancer, and more broadly the promise of RNAi therapeutics in oncology.”

In the second portion of the trial, the company will assess the two most efficacious dosing regimens of the drug.

The proportion of participants with histological clearance of treated isSCC lesion at the end of treatment form the primary endpoint of the trial.

Sirnaomics chief medical officer Michael Molyneaux said: “isSCC continues to be a disease with high unmet therapeutic need where surgery is still considered the only viable treatment option for many patients.

“We hope to build on the success we have seen in the Phase IIa study, where we achieved 90% histological clearance rates in the 30ug and 60ug dosing groups.”

The company expects to report initial clinical data in the second half of this year.